CTLA4 and neoplasm: In the Phase I study of the bsAb KN046 [102], targeting PD-L1 and CTLA-4, exploratory analyses of biomarkers were conducted in 93 patients with advanced solid tumors, evaluating tumor PD-L1 expression.